What happens when you take apixaban with St. John's wort?
Apixaban (Eliquis) is a direct oral anticoagulant that blocks Factor Xa to prevent and treat blood clots. It is primarily metabolized by the liver enzyme CYP3A4 and is also a substrate of the P-glycoprotein (P-gp) efflux pump. Anything that revs up either of these systems will pull apixaban out of the bloodstream faster than expected.
St. John's wort (Hypericum perforatum) is among the most powerful natural inducers known. Its active constituent hyperforin activates the pregnane X receptor (PXR), which in turn ramps up production of CYP3A4 and P-glycoprotein. Within roughly 10 to 14 days of regular use, apixaban exposure can be cut substantially because the body is both metabolizing it and pumping it out more aggressively.
The result is lower-than-intended apixaban levels and weaker anticoagulant effect, even though the patient is still taking the prescribed dose every day.
Why is this important?
Apixaban is prescribed to prevent strokes in atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism, and to prevent recurrence of clots. These are high-stakes indications where falling below the therapeutic range can lead directly to a stroke, a clot, or death.
The FDA-approved label for Eliquis explicitly warns against combining apixaban with strong dual inducers of CYP3A4 and P-gp, naming rifampin, carbamazepine, phenytoin, and St. John's wort. Unlike with warfarin, where INR testing would catch under-anticoagulation, apixaban is given at fixed doses without routine blood monitoring. The interaction is invisible until something goes wrong.
The reverse problem (bleeding from interactions with inhibitors like ketoconazole or ritonavir) is well known. But induction by St. John's wort is the more silent and arguably more dangerous version, because patients can feel fine right up until they have a stroke.
What should you do?
Do not combine St. John's wort with apixaban. If you are about to start apixaban and currently take St. John's wort, stop the supplement before your first dose and let your prescriber know, since enzyme and transporter levels take one to two weeks to normalize.
If you have been taking apixaban and started St. John's wort, contact your prescriber rather than guessing. They may want to switch you to a different antidepressant approach, increase monitoring, or in some cases consider a different anticoagulant strategy.
For depression, evidence-based prescription options (SSRIs, SNRIs, bupropion) and non-drug therapies (cognitive behavioral therapy, behavioral activation, exercise) are safer alongside apixaban, although SSRIs themselves carry a small added bleeding risk that your prescriber will factor in.
While on apixaban, learn the warning signs of inadequate anticoagulation: sudden one-sided weakness, facial droop, slurred speech, vision changes, severe sudden headache, chest pain, sudden shortness of breath, or new unilateral leg swelling. Any of these warrant immediate emergency care.
Which specific products are affected?
This applies to apixaban (Eliquis) at all approved doses (2.5 mg and 5 mg). The same CYP3A4/P-gp induction concern applies to the other DOACs in different proportions: rivaroxaban (Xarelto), dabigatran (Pradaxa, primarily P-gp), and edoxaban (Savaysa, Lixiana).
On the supplement side, look for St. John's wort, Hypericum perforatum, hypericin, or hyperforin on the label of any mood-support, stress-relief, sleep, or general wellness product. Standardized extracts (typically 0.3% hypericin or 3 to 5% hyperforin) are the most potent inducers, but lower-grade preparations should also be avoided.
The bottom line
The combination of apixaban and St. John's wort is one of the few herb-drug interactions explicitly flagged on the FDA label of the medication itself, and for good reason. St. John's wort can quietly lower apixaban levels to a point where it no longer protects you from clots. If you take apixaban, do not take St. John's wort. If you are taking both today, call your prescriber today.